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ORIGINAL RESEARCHPrioritizing Needs and Outcomes for Adolescent
Substance Use Treatment Planning: An Online
Modified-Delphi ProcessSean Grant, DPhil, Eric R. Pedersen, PhD, Sarah B. Hunter, PhD,
Dmitry Khodyakov, PhD, and Beth Ann Griffin, PhDObjectives: Key stakeholders can have differing views about which
information is essential to inform placement decisions for all
patients. This study examined consensus across stakeholder groups
on the most important individual needs and treatment outcomes for
informing decisions specifically about the level of care for an
adolescent in substance use treatment.
Methods: We conducted an online modified-Delphi process with
treatment providers, policymakers, researchers, and parents of ado-
lescents who have received substance use treatment. Participants rated
48 individual needs from the Global Appraisal of Individual Needs–
Initial that were mapped onto the 6 dimensions of the American
Society of Addiction Medicine Criteria. In addition, participants rated
10 treatment outcomes from the Substance Abuse and Mental Health
Services Administration’s National Outcome Measures. We assessed
consensus within stakeholder groups using the RAND/UCLA Appro-
priateness Method. We considered the items reaching consensus with
the highest ratings across stakeholder groups as the most important
individual needs and treatment outcomes.
Results: We recruited 194 participants (81 providers, 54 policy-
makers, 32 researchers, 27 parents). Participants identified suicidal-
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J Addict Med  Volume 14, Number 4, July/August 2020important individual needs, and reduction in substance use as the
most important treatment outcome.
Conclusions: Standardized procedures for matching adolescents to
levels of care for substance use treatment should at a minimum be
based on assessments of suicidality and severity of substance use
disorder symptoms, and consider reduction in substance use as a
primary treatment outcome. These findings can progress the devel-
opment of ‘‘level-of-care’’ decision rules specifically for adolescents.
Key Words: adolescent, Delphi technique, substance-related
disorders
(J Addict Med 2020;14: e83–e88)
A pproximately 1 million adolescents in the United Statesmeet substance use disorder (SUD) criteria (SAMHSA,
2018). While many treatments for adolescent substance use
exist (Das et al., 2016), individual adolescents respond dif-
ferentially to treatment based on their unique medical, psy-
chological, and social needs, as well as the outcomes used to
measure progress and success (National Institute on Drug
Abuse, 2014). Much attention has therefore recently focused
on developing measurement instruments and placement cri-
teria that match each adolescent to their most appropriate level
of care (Fishman, 2014). However, a pragmatic barrier to
integrating these multidimensional patient assessments into
the treatment planning process is the substantial number of
needs and outcomes to potentially consider (Winters et al.,
2014). For example, treatment providers often consider the
time it takes to administer an assessment tool, with longer
tools less likely to be integrated into routine clinical practice
(Hamilton et al., 2008). To address this barrier, developers of
prominent instruments offer briefer versions that assess the
most important individual needs and treatment outcomes
(Dennis et al., 2003).
Key stakeholders can have differing views about which
individual needs and treatment outcomes are most important
for treatment planning, based on their diverse experiences and
perspectives. Policymakers prefer clinical indicators and out-
comes that best fit the resources, personnel, and financing of
their clinics and systems (Sterling et al., 2010). Adolescents
and their parents frequently identify a range of non-clinicale83
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(Acri et al., 2012). Researchers are likely to focus on items
with more robust evidence and high-quality measurement
instruments (McGovern and Carroll, 2003). Identifying the
individual needs and treatment outcomes that all key stake-
holder groups consider of higher importance could serve as an
important step toward improving the development and imple-
mentation of patient placement criteria for adolescents enter-
ing substance use treatment.
METHODS
This study is part of a larger project that combines
stakeholder engagement with modern statistical methods to
develop well-operationalized, empirically-supported sequen-
ces of decision rules for placing adolescents with SUDs in
appropriate settings (Grant et al., 2017). Study procedures
were given exempt status by the RAND Human Subjects
Protection Committee (ID 2015-0268-AM01), and the proto-
col and materials can be found on the Open Science Frame-
work (https://osf.io/bqbrw/).
Participants
We conducted an online modified-Delphi process con-
sisting of 4 concurrent panels (1 for each stakeholder group):
providers of adolescent substance use treatment; policy-
makers overseeing program planning at the clinic, health-
system, state, or federal levels; researchers of adolescent
substance use treatment; and parents of adolescents who have
received substance use treatment. We approached stakehold-
ers identified through published research; member lists of
relevant organizations; treatment centers listed in the Sub-
stance Abuse and Mental Health Services Administration
(SAMHSA) Treatment Locator; and suggestions from the
wider project team, advisory board, and stakeholders we
approached via the above mechanisms. We sent identified
stakeholders an email with a link to our recruitment survey
and informed them that they would receive a $200 Amazon
gift card for completing the online panel. We aimed to recruit
20 to 40 participants per panel—a manageable size that
included a diverse and significant group of stakeholders
(Khodyakov et al., 2011).
Procedures
Our recruitment survey asked stakeholders to indicate
their interest in participating in the study and complete a
demographics questionnaire. We then sent interested stake-
holders a link to RAND’s ExpertLens web-based system for a
three-round, online Delphi process (Dalal et al., 2011). We
developed a list of specific individual needs and treatment
outcomes using the Global Appraisal of Individual Needs–
Initial (GAIN-I) instrument (Dennis et al., 2003). Participants
rated 48 individual needs from the GAIN-I that map onto the 6
dimensions of the American Society of Addiction Medicine
Criteria and 10 treatment outcomes from the GAIN-I that map
onto the SAMHSA National Outcome Measures (NOMs). In
Round One, participants used a 9-point Likert scale (1¼ lower
importance to 9¼ higher importance) to rate the importance of
assessing the 48 individual needs and 10 treatment outcomes
for deciding the appropriate level of care (outpatient, intensivee84  2020 The Author(s). Published by Wolters Kluwer Heoutpatient, residential, or inpatient) for an adolescent’s sub-
stance use treatment. In Round Two, participants received
feedback on Round One results: each participant saw graphed
results (histogram with the median rating and their own rating
for each item) and decisions about the group’s consensus on the
importance of items. In Round Three, participants re-rated each
item in light of Round Two feedback.
Data Analysis
We first conducted a descriptive analysis of participant
demographics and item ratings. We then assessed consensus
within each panel using the inter-percentile range adjusted for
symmetry (IPRAS) technique from the RAND/UCLA Appro-
priateness Method (Fitch et al., 2001). IPRAS initially deter-
mines whether there is disagreement (ie, uncertain importance)
based onthe dispersionof ratings; if there isnodisagreement, the
median rating indicates group consensus (ie, a median between
1-to-3 indicates ‘‘lower importance’’, 4-to-6 ‘‘moderate impor-
tance’’, 7-to-9 ‘‘higher importance’’). We considered items of
‘‘higher importance’’witha medianof8or9 ineverypanel as the
most important individual needs and treatment outcomes.
RESULTS
Of 281 invited stakeholders, 194 (69%) participated
(see Table 1). Participants predominantly were female (71%),
were 35 to 54 years old (57%), had a bachelor’s or master’s
degree (73%), were Caucasian/White (80%), lived in urban
communities (71%), and had experience with outpatient set-
tings (78%) for either cannabis (88%) or alcohol (87%). No
items had uncertain importance within a panel (see Table 2).
Two individual needs were identified as the most important:
suicidality (‘‘thoughts of, plans for, actions toward, or
attempted suicide’’) and severity of SUD symptoms (‘‘extent
of physiological, psychological, and social problems related
to substance use’’). One treatment outcome was identified as
most important: reduction in substance use (‘‘the degree to
which the adolescent has reduced the quantity and frequency
of their substance use by the end of treatment’’). Moreover,
every stakeholder group considered an additional 15 individ-
ual needs and seven treatment outcomes of higher importance.
The 2 highest-rated of the 7 additional treatment outcomes
match the most important needs: that is, reduction in sub-
stance use disorder symptoms (‘‘the degree to which the
adolescent has experienced a reduction in their symptoms
of substance use disorder by the end of treatment’’) and
improved mental health (‘‘the degree to which the adolescent
has experienced an improvement in their mental health
symptoms by the end of treatment’’). Of the remaining items,
7 individual needs and 1 treatment outcome were considered
of higher importance in only 3 panels, 5 individual needs and
1 treatment outcome of higher importance in only 2 panels, 7
individual needs of higher importance in only 1 panel, and 12
individual needs of higher importance in no panels. Only 1
item—the adolescent client’s spiritual environment—was
considered of lower importance by any panel.
DISCUSSION
We engaged 194 stakeholders in an online modified-
Delphi process to examine consensus on the relativealth, Inc. on behalf of the American Society of Addiction Medicine.
TABLE 1. Participant Demographics
Demographic Total (n¼ 194) Providers (n¼ 81) Policymakers (n¼ 54) Researchers (n¼ 32) Parents (n¼ 27)
Gender
Female 138 (71%) 65 (80%) 36 (67%) 21 (66%) 16 (59%)
Male 51 (26%) 14 (17%) 16 (30%) 10 (31%) 11 (41%)
Not reported 5 (3%) 2 (3%) 2 (4%) 1 (3%) —
Age
18–24 3 (2%) 3 (4%) — — —
25–34 33 (17%) 20 (25%) 5 (9%) 5 (16%) 3 (11%)
35–44 56 (29%) 26 (32%) 18 (33%) 7 (22%) 5 (19%)
45–54 55 (28%) 17 (21%) 18 (33%) 9 (28%) 11 (41%)
55–64 37 (19%) 12 (15%) 10 (19%) 8 (25%) 7 (26%)
65 and older 8 (4%) 2 (3%) 3 (6%) 2 (6%) 1 (4%)
Not reported 2 (1%) 1 (1%) — 1 (3%) —
Education
High school 1 (1%) — — — 1 (4%)
Some college 5 (3%) — — 1 (3%) 4 (15%)
Associate’s degree 4 (2%) 1 (1%) 1 (2%) — 2 (7%)
Bachelor’s degree 45 (23%) 16 (20%) 13 (24%) 2 (6%) 14 (52%)
Master’s degree 97 (50%) 56 (69%) 32 (59%) 4 (13%) 5 (19%)
Professional degree 5 (3%) 2 (3%) 3 (6%) - —
Doctoral degree 36 (19%) 5 (6%) 5 (9%) 25 (78%) 1 (4%)
Not reported 1 (1%) 1 (1%) — — —
Hispanic origin
Yes 13 (7%) 4 (5%) 5 (9%) 4 (13%) —
No 180 (93%) 76 (94%) 49 (91%) 28 (88%) 27 (100%)
Not reported 1 (1%) 1 (1%) — — —
Race
African American/Black 19 (10%) 9 (11%) 5 (9%) 2 (6%) 3 (11%)
American Indian/Alaska Native 3 (2%) — 3 (6%) 2 (6%) —
Asian 6 (3%) 3 (4%) 1 (2%) — —
Caucasian/White 155 (80%) 64 (79%) 41 (76%) 26 (81%) 24 (89%)
Hispanic, Latino, or Chicano 10 (5%) 3 (4%) 5 (9%) 2 (6%) —
Native American 1 (1%) 1 (1%) — — —
Other 1 (1%) 1 (1%) — — —
Not reported 2 (1%) 1 (1%) — 1 (3%) —
Region of United States
Northeast 47 (24%) 18 (22%) 10 (19%) 10 (31%) 9 (33%)
Midwest 45 (23%) 24 (30%) 10 (19%) 7 (22%) 4 (15%)
South 57 (29%) 23 (28%) 20 (37%) 3 (9%) 11 (41%)
West 44 (23%) 15 (19%) 14 (26%) 12 (38%) 3 (11%)
Not reported 1 (1%) 1 (1%) — — —
Community
Rural 55 (28%) 27 (33%) 15 (28%) 7 (22%) 6 (22%)
Urban 138 (71%) 53 (65%) 39 (72%) 25 (78%) 21 (78%)
Not reported 1 (1%) 1 (1%) — — —
Treatment Settings
Outpatient 152 (78%) 67 (83%) 46 (85%) 27 (84%) 12 (44%)
Intensive outpatient 88 (45%) 29 (36%) 26 (48%) 16 (50%) 17 (63%)
Residential 71 (37%) 18 (22%) 24 (44%) 13 (41%) 16 (59%)
Inpatient 31 (16%) 2 (2%) 18 (33%) 7 (22%) 4 (15%)
Other 2 (1%) — — — 2 (7%)
Substances Used by Adolescents
Alcohol 168 (87%) 80 (99%) 47 (87%) 28 (88%) 13 (48%)
Amphetamines 117 (60%) 59 (73%) 34 (63%) 16 (50%) 8 (30%)
Cannabis 171 (88%) 81 (100%) 48 (89%) 26 (81%) 16 (59%)
Cocaine 114 (59%) 54 (67%) 35 (65%) 16 (50%) 9 (33%)
Hallucinogens 111 (57%) 55 (68%) 35 (65%) 14 (44%) 7 (26%)
Heroin 104 (54%) 48 (59%) 37 (69%) 16 (50%) 3 (11%)
Inhalants 97 (50%) 52 (64%) 32 (59%) 10 (31%) 3 (11%)
Methamphetamine 98 (51%) 49 (60%) 34 (63%) 12 (38%) 3 (11%)
Over-the-counter medicines 119 (61%) 61 (75%) 39 (72%) 14 (44%) 5 (19%)
PCP 74 (38%) 21 (26%) 25 (46%) 27 (84%) 1 (4%)
Prescription medicines 134 (69%) 63 (78%) 45 (83%) 17 (53%) 9 (33%)
Sedative, Hypnotic, or Anxiolytic 89 (46%) 46 (57%) 30 (56%) 9 (28%) 4 (15%)
Synthetic cannabis 121 (62%) 60 (74%) 43 (80%) 14 (44%) 4 (15%)
Tobacco/Nicotine 136 (70%) 72 (89%) 42 (78%) 13 (41%) 9 (33%)
Other 19 (10%) 8 (10%) 2 (4%) 5 (16%) 4 (15%)
Adolescent Ages
Early Adolescence (11–13 years) 63 (58%) 56 (69%) N/A N/A 7 (26%)
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TABLE 1 (Continued)
Demographic Total (n¼ 194) Providers (n¼ 81) Policymakers (n¼ 54) Researchers (n¼ 32) Parents (n¼ 27)
Middle Adolescence (14–16 years) 89 (82%) 73 (90%) N/A N/A 16 (59%)
Late Adolescence (17þ years) 83 (78%) 77 (95%) N/A N/A 6 (22%)
Treatment Referrals Methods
Mandated (justice system, school) 88 (81%) 78 (96%) N/A N/A 10 (37%)
Recommendation by service provider 8 (30%) N/A N/A N/A 8 (30%)
Request of family 18 (67%) N/A N/A N/A 18 (67%)
Self-initiated 3 (11%) N/A N/A N/A 3 (11%)
Other 2 (7%) N/A N/A N/A 2 (7%)
Treatment Financing
Public insurance 81 (75%) 71 (88%) N/A N/A 10 (37%)
Private insurance 60 (56%) 44 (54%) N/A N/A 16 (59%)
Out of pocket 44 (41%) 30 (37%) N/A N/A 14 (52%)
Other 27 (25%) 25 (31%) N/A N/A 2 (7%)
Notes: ‘‘N/A’’: not applicable for this stakeholder group.
Percentages in ‘‘Total’’ column based on sample size of applicable stakeholder groups.
TABLE 2. Rating Results From Round Three
Providers Policymakers Researchers Parents
Dimension Item Median Decision Median Decision Median Decision Median Decision
Acute Intoxication and
Withdrawal Potential
Frequency of substance use 8 þ 9 þ 8 þ 7 þ
Behavioral withdrawal symptoms 8 þ 9 þ 8 þ 7 þ
Time recently spent in a detoxification program 8 þ 8 þ 8 þ 7 þ
Physiological withdrawal symptoms 8 þ 8 þ 8 þ 6 
Psychological withdrawal symptoms 7 þ 6.5  7 þ 7 þ
Time recently spent in a controlled environment 7 þ 6  5  6 
Biomedical Conditions
and Complications
Substance use involving needles 8 þ 8 þ 8 þ 7 þ
Worsening of physical health due to substance
use
8 þ 7 þ 7.5 þ 7 þ
Infectious diseases and illnesses 6  6  7 þ 6 
Interference of physical health problems with
responsibilities
6  6  6  7 þ
History of health care utilization 5  6  7 þ 6 
Sexual behaviors 5  6  5  7 þ
General complaints about physical health 5  6  5  5 




Suicidality 9 þ 9 þ 9 þ 8 þ
History of mental health treatment 7 þ 8 þ 8 þ 8 þ
Violent behavior 8 þ 8 þ 8 þ 7 þ
Cognitive impairment 8 þ 8 þ 7 þ 7 þ
Depressive symptoms 7 þ 8 þ 7 þ 7 þ
Traumatic stress symptoms 7 þ 8 þ 6.5  7 þ
Personality disorder symptoms 6  7 þ 7 þ 7 þ
General complaints about mental health 7 þ 7 þ 6  6 
Anxiety symptoms 7 þ 6  6  7 þ
Conduct disorder symptoms 7 þ 6  6  7 þ
Illegal activity 6  7 þ 5  7 þ
Engagement with criminal justice system 6  6  5  6 
Somatic symptoms 5  5  5  6 
Attention and hyperactivity symptoms 5  5  4  6 
Readiness to Change Treatment motivation 7 þ 7 þ 6  8 þ
Personal reasons for wanting to quit using
substances
7 þ 7 þ 5.5  7 þ
Perceived difficulties of engaging in treatment 6  6  6  6 
Perceived external pressure to change substance
use behavior
6  5  5  6 
Perceived need for treatment 5  5  5  6 
Perceived external pressure to engage in
treatment
5  4  5  5.5 
Relapse, Continued Use,
or Continued Problem Potential
Severity of substance use disorder 8 þ 8 þ 8 þ 8 þ
Continued use despite treatment 8 þ 8 þ 8 þ 7 þ
Recent substance use treatment 7 þ 8 þ 7 þ 7 þ
Perceived ability to change substance use
behavior
5  5.5  5  7 þ
Self-confidence in resisting relapse 5  5  5  6 
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TABLE 2 (Continued)
Providers Policymakers Researchers Parents
Dimension Item Median Decision Median Decision Median Decision Median Decision
Recovery/Living Environment Adolescent’s living environment 8 þ 8 þ 7 þ 8 þ
Adolescent’s social network 8 þ 8 þ 7 þ 8 þ
Parent involvement in adolescent’s life 8 þ 8 þ 7 þ 8 þ
Engagement in structured substance-free
activities
7 þ 8 þ 7 þ 7.5 þ
Involvement with Child Protective Services 6  7 þ 7 þ 7 þ
Adolescent’s school/work environment 6  7 þ 5  7 þ
Satisfaction with living/recovery environment 6.5  7 þ 5  6 
Financial issues 5  5  5.5  6 
Adolescent client’s spiritual environment 5  5  3 - 5 
Treatment Outcomes Reduction in substance use 8 þ 8 þ 8 þ 8 þ
Reduction in substance use disorder symptoms 8 þ 8 þ 8 þ 7 þ
Improved mental health 8 þ 8 þ 7 þ 8 þ
Completion of treatment plan 7 þ 8 þ 7 þ 8 þ
Engagement in school/work 7 þ 8 þ 7 þ 8 þ
Improved relationships in the home and family 7 þ 8 þ 7 þ 8 þ
Stable housing 7 þ 8 þ 7 þ 7 þ
Reduced engagement in illegal activities 7 þ 7 þ 7 þ 7 þ
Abstinence from substance use 8 þ 6  7 þ 8 þ
Improved physical health 6  7 þ 6  7 þ
Notes: ‘‘þ’’ indicates higher importance (median score of 7–9, without disagreement), ‘‘ ’’ indicates moderate importance (median score of 4–6, without disagreement), and ‘‘-‘‘
indicates lower importance (median score of 1–3, without disagreement). A ‘‘’’ indicates that every stakeholder group considered that item of higher importance.
J Addict Med  Volume 14, Number 4, July/August 2020 Adolescent Sud Delphiimportance of individual needs and treatment outcomes for
informing level of care recommendations for adolescents
entering substance use treatment. Stakeholders agreed that
suicidality and severity of SUD symptoms were the most
important of 48 individual needs, and that reduction in sub-
stance use was the most important of 10 treatment outcomes.
Every stakeholder group also agreed on an additional 15
individual needs and 7 treatment outcomes as highly important,
and the 2 highest-rated of these 7 additional treatment outcomes
match the most important needs: that is, ‘‘reduction in sub-
stance use disorder symptoms’’ and ‘‘improved mental health’’
(which includes suicide ideation, planning, and attempts).
These findings reflect the items included in even the briefer
versions of measurement instruments linked to patient place-
ment criteria, which professionals involved in adolescent sub-
stance use treatment planning can use to assess the individual
needs and treatment outcomes deemed highly important by
stakeholders in this study (Dennis et al., 2003; Hamilton et al.,
2008; Fishman, 2014; Winters et al., 2014).
Several limitations are worth noting in interpreting the
results of this study. First, as with all Delphi processes, our
participants are not a representative sample of all relevant
stakeholders. While we recruited a much larger sample than
traditional online panels, the results of this project may be
biased towards stakeholder sub-samples with Internet access,
available time to respond, and stakeholders who identify as
White and non-Hispanic. Second, this project was focused on
a US-context; while results may have relevance to other
countries and healthcare systems, these findings are more
applicable to a US population—particularly those with expe-
rience in urban and outpatient settings. Lastly, Delphi pro-
cesses involve self-report surveys designed to explore and
develop consensus, leaving results subject to the facets,
challenges, and limitations inherent to this study design
and measurement format. 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on beMatching individual adolescents to the most appropriate
level of care is challenging, particularly due to the substantial
range of individual needs and treatment outcomes to poten-
tially consider. Findings suggest that multiple stakeholder
groups consider suicidality, severity of SUD symptoms,
and reduction in substance use as essential to inform level
of care decisions for every adolescent entering substance use
treatment. These findings can progress the development of
‘‘level-of-care’’ decision rules specifically for adolescents.
For example, the individual needs and treatment goals identi-
fied as important by all stakeholder groups will be prioritized
during later stages of our project for the development and
testing of well-operationalized, empirically-supported
sequences of decision rules for placing adolescent clients
with SUDs in appropriate settings (Grant et al., 2017). In
the interim, standardized procedures for matching adolescents
to levels of care for substance use treatment should at a
minimum be based on assessments of suicidality and severity
of substance use disorder symptoms, and consider reduction
in substance use as a primary treatment outcome.REFERENCES
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